(Q36389681)

English

Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26647006%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26647006%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

multiple sclerosis

0 references

0 references

Giuseppe Salemi

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26647006%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Antonio Bertolotto

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26647006%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Marianna Lo Re

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26647006%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Marco Capobianco

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26647006%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Paolo Ragonese

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26647006%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Sabrina Realmuto

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26647006%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Simona Malucchi

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26647006%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Paola Berchialla

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26647006%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

8 December 2015

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26647006%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Neurology and therapy

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26647006%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26647006%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26647006%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

147-157

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26647006%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

https://scigraph.springernature.com/pub.10.1007/s40120-015-0038-9

0 references

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

30 September 2017

Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

30 September 2017

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

30 September 2017

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

30 September 2017

Fingolimod after natalizumab and the risk of short-term relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

30 September 2017

Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

30 September 2017

PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

30 September 2017

Progressive multifocal leukoencephalopathy in patients with multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

30 September 2017

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

30 September 2017

Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

30 September 2017

Course of relapsing-remitting multiple sclerosis before, during and after natalizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

30 September 2017

Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

30 September 2017

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

30 September 2017

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

30 September 2017

Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

30 September 2017

Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

21 September 2018

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

21 September 2018

Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

21 September 2018

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

21 September 2018

Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

21 September 2018

Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

21 September 2018

Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

21 September 2018

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

21 September 2018

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

21 September 2018

Natalizumab: bound to rebound?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

21 September 2018

Immune surveillance in multiple sclerosis patients treated with natalizumab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

21 September 2018

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4685862

21 September 2018

Severe relapses under fingolimod treatment prescribed after natalizumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/26647006

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation

1 reference

https://pubmed.ncbi.nlm.nih.gov/26647006

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26647006

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Observations during an elective interruption of natalizumab treatment: a post-marketing study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26647006

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26647006

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Considerations on discontinuing natalizumab for the treatment of multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26647006

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26647006

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/26647006

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26647006

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natalizumab dosage suspension: are we helping or hurting?

1 reference

https://pubmed.ncbi.nlm.nih.gov/26647006

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40120-015-0038-9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26647006%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26647006%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26647006%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36389681&oldid=1518981928"